More on PDI (PDII): Shares are soaring in the post session after posting a Q1 EPS report that...

|By:, SA News Editor

More on PDI (PDII): Shares are soaring in the post session after posting a Q1 EPS report that blew away Street estimates. Its bottom-line EPS leapt 800% from the same quarter last year, as total sales grew by 36% over the same period. Operating income swung to a profit on the quarter, largely due to cost cutting efforts and the signing of a $17M multi-year sales contract for which PDII will provide a dedicated team to promote a CNS therapeutic product to neurologists and pain specialists. Shares +30% AH.